MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)
Condition: Diabetes Mellitus, Type 1 Intervention: Drug: Anti-Human Thymocyte Immunoglobulin, Rabbit Sponsor: Universitaire Ziekenhuizen Leuven Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials